Flamel Technologies (FLML) 13.37 $FLML
Flamel Technologies Hires Vice President of Sales
Marketwired - Wed Aug 31, 3:03PM CDT
LYON, FRANCE--(Marketwired - Aug 31, 2016) - Flamel Technologies (NASDAQ: FLML) today announced that Mark W. Elrod has joined the Company as Vice President, Sales. Mr. Elrod will be responsible for managing sales across all of the Company's commercialized products.
FLML: 13.37 (unch)
21.5% Return Seen to Date on SmarTrend Flamel Technologies Call (FLML)
Comtex SmarTrend(R) - Fri Aug 26, 1:07AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on July 7th, 2016 at $11.26. In approximately 2 months, Flamel Technologies has returned 21.46% as of today's recent price of $13.67.
FLML: 13.37 (unch)
Flamel Technologies Shares Up 25.0% Since SmarTrend's Buy Recommendation (FLML)
Comtex SmarTrend(R) - Thu Aug 18, 1:36PM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on July 7th, 2016 at $11.26. In approximately 1 month, Flamel Technologies has returned 25.01% as of today's recent price of $14.07.
FLML: 13.37 (unch)
Flamel Technologies Launches Akovaz(TM)
Marketwire Canada - Fri Aug 12, 6:32AM CDT
LYON, FRANCE--(Marketwired - Aug 12, 2016) - Flamel Technologies (NASDAQ: FLML) today announced the launch of Akovaz™, its formulation of ephedrine sulfate for injection, which received approval from the U.S. Food and Drug Administration (FDA) on April 29, 2016. Ephedrine sulfate (50 mg/mL) is a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings.
FLML: 13.37 (unch)
Flamel Technologies Announces Shareholder Approval of Cross-Border Merger
Marketwired - Fri Aug 12, 6:30AM CDT
Company to Reincorporate in Ireland
FLML: 13.37 (unch)
Flamel Technologies Reports Second Quarter 2016 Results
Marketwire Canada - Mon Aug 08, 6:30AM CDT
Total Revenues of $38.9 Million; 2016 Revenue Guidance Increased to $125 to $140 Million; Akovaz™ to Launch in August 2016
FLML: 13.37 (unch)
Flamel Technologies to Present at Two Upcoming Investor Conferences
Marketwired - Wed Jun 01, 6:30AM CDT
LYON, FRANCE--(Marketwired - Jun 1, 2016) - Flamel Technologies (NASDAQ: FLML) today announced that management will present at two upcoming investor conferences:
FLML: 13.37 (unch)
Flamel Technologies Reports First Quarter 2016 Results
Marketwire Canada - Mon May 09, 6:30AM CDT
Total Revenues of $36.2 Million; Adjusted Net Income of $1.6 Million and Adjusted Diluted EPS of $0.04; Adjusted EBITDA of $11.8 Million; Cash Flow From Operations of $22.5 Million
FLML: 13.37 (unch)
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:19AM CDT
However, a few companies are still yet to report quarterly numbers. Let's see what we can expect from a few drug stocks reporting earnings early next week.
BIIB: 305.63 (unch), ABT: 42.02 (unch), JNJ: 119.34 (unch), FLML: 13.37 (unch), IRWD: 13.34 (unch), GILD: 78.38 (unch), AMGN: 170.06 (unch), FGEN: 17.31 (-0.37), ENTA: 21.99 (unch), NVS: 78.77 (unch)
Flamel Technologies to Report First Quarter 2016 Results
Marketwired - Mon May 02, 3:05PM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the Company will report its financial results for the first quarter ended March 31, 2016 on Monday, May 9, 2016, before the market open. A conference call to discuss these results has been scheduled for Monday, May 9, 2016 at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
FLML: 13.37 (unch)
Flamel Technologies Receives FDA Approval of Akovaz(TM)
Marketwired - Mon May 02, 6:30AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's New Drug Application (NDA) for Akovaz(TM) (ephedrine sulfate), a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings. Flamel obtained NDA approval for Akovaz as scheduled on April 29 and is the first to receive approval from the FDA for ephedrine sulfate. Flamel expects to launch Akovaz during the third quarter 2016 in a strength of 50 mg/mL.
FLML: 13.37 (unch)
Flamel Technologies to Present at Upcoming Investor Conferences
Marketwired - Fri Apr 22, 3:05PM CDT
Flamel Technologies (NASDAQ: FLML) today announced that management will present at two upcoming investor conferences. Michael Anderson, Chief Executive Officer, and Mike Kanan, Chief Financial Officer, are scheduled to present at the following:
FLML: 13.37 (unch)
Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate
Marketwired - Thu Mar 31, 7:00AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for the pivotal Phase III study of its once nightly Micropump(TM) based sodium oxybate product. The SPA will provide the FDA an opportunity to review and comment on the company's planned study design, and once accepted, offers general acknowledgement by the FDA that the trial's design, clinical endpoints and statistical analyses are acceptable and support the scientific and regulatory requirements associated with the product.
FLML: 13.37 (unch)
Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions
ACCESSWIRE - Mon Mar 28, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / DURECT Corporation (NASDAQ: DRRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Flamel Technologies SA (NASDAQ: FLML), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
FLML: 13.37 (unch), VNDA: 15.38 (-0.34), GNCA: 5.36 (-0.03), DRRX: 1.67 (-0.04)
Flamel Technologies Hires Vice President of Sales
Marketwired - Wed Aug 31, 3:03PM CDT
LYON, FRANCE--(Marketwired - Aug 31, 2016) - Flamel Technologies (NASDAQ: FLML) today announced that Mark W. Elrod has joined the Company as Vice President, Sales. Mr. Elrod will be responsible for managing sales across all of the Company's commercialized products.
FLML: 13.37 (unch)
21.5% Return Seen to Date on SmarTrend Flamel Technologies Call (FLML)
Comtex SmarTrend(R) - Fri Aug 26, 1:07AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on July 7th, 2016 at $11.26. In approximately 2 months, Flamel Technologies has returned 21.46% as of today's recent price of $13.67.
FLML: 13.37 (unch)
Flamel Technologies Shares Up 25.0% Since SmarTrend's Buy Recommendation (FLML)
Comtex SmarTrend(R) - Thu Aug 18, 1:36PM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on July 7th, 2016 at $11.26. In approximately 1 month, Flamel Technologies has returned 25.01% as of today's recent price of $14.07.
FLML: 13.37 (unch)
Flamel Technologies Launches Akovaz(TM)
Marketwire Canada - Fri Aug 12, 6:32AM CDT
LYON, FRANCE--(Marketwired - Aug 12, 2016) - Flamel Technologies (NASDAQ: FLML) today announced the launch of Akovaz™, its formulation of ephedrine sulfate for injection, which received approval from the U.S. Food and Drug Administration (FDA) on April 29, 2016. Ephedrine sulfate (50 mg/mL) is a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings.
FLML: 13.37 (unch)
Flamel Technologies Announces Shareholder Approval of Cross-Border Merger
Marketwired - Fri Aug 12, 6:30AM CDT
Company to Reincorporate in Ireland
FLML: 13.37 (unch)
Flamel Technologies Reports Second Quarter 2016 Results
Marketwire Canada - Mon Aug 08, 6:30AM CDT
Total Revenues of $38.9 Million; 2016 Revenue Guidance Increased to $125 to $140 Million; Akovaz™ to Launch in August 2016
FLML: 13.37 (unch)
Flamel Technologies to Present at Two Upcoming Investor Conferences
Marketwired - Wed Jun 01, 6:30AM CDT
LYON, FRANCE--(Marketwired - Jun 1, 2016) - Flamel Technologies (NASDAQ: FLML) today announced that management will present at two upcoming investor conferences:
FLML: 13.37 (unch)
Flamel Technologies Reports First Quarter 2016 Results
Marketwire Canada - Mon May 09, 6:30AM CDT
Total Revenues of $36.2 Million; Adjusted Net Income of $1.6 Million and Adjusted Diluted EPS of $0.04; Adjusted EBITDA of $11.8 Million; Cash Flow From Operations of $22.5 Million
FLML: 13.37 (unch)
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:19AM CDT
However, a few companies are still yet to report quarterly numbers. Let's see what we can expect from a few drug stocks reporting earnings early next week.
BIIB: 305.63 (unch), ABT: 42.02 (unch), JNJ: 119.34 (unch), FLML: 13.37 (unch), IRWD: 13.34 (unch), GILD: 78.38 (unch), AMGN: 170.06 (unch), FGEN: 17.31 (-0.37), ENTA: 21.99 (unch), NVS: 78.77 (unch)
Flamel Technologies to Report First Quarter 2016 Results
Marketwired - Mon May 02, 3:05PM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the Company will report its financial results for the first quarter ended March 31, 2016 on Monday, May 9, 2016, before the market open. A conference call to discuss these results has been scheduled for Monday, May 9, 2016 at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
FLML: 13.37 (unch)
Flamel Technologies Receives FDA Approval of Akovaz(TM)
Marketwired - Mon May 02, 6:30AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's New Drug Application (NDA) for Akovaz(TM) (ephedrine sulfate), a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings. Flamel obtained NDA approval for Akovaz as scheduled on April 29 and is the first to receive approval from the FDA for ephedrine sulfate. Flamel expects to launch Akovaz during the third quarter 2016 in a strength of 50 mg/mL.
FLML: 13.37 (unch)
Flamel Technologies to Present at Upcoming Investor Conferences
Marketwired - Fri Apr 22, 3:05PM CDT
Flamel Technologies (NASDAQ: FLML) today announced that management will present at two upcoming investor conferences. Michael Anderson, Chief Executive Officer, and Mike Kanan, Chief Financial Officer, are scheduled to present at the following:
FLML: 13.37 (unch)
Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate
Marketwired - Thu Mar 31, 7:00AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for the pivotal Phase III study of its once nightly Micropump(TM) based sodium oxybate product. The SPA will provide the FDA an opportunity to review and comment on the company's planned study design, and once accepted, offers general acknowledgement by the FDA that the trial's design, clinical endpoints and statistical analyses are acceptable and support the scientific and regulatory requirements associated with the product.
FLML: 13.37 (unch)
Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions
ACCESSWIRE - Mon Mar 28, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / DURECT Corporation (NASDAQ: DRRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Flamel Technologies SA (NASDAQ: FLML), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
FLML: 13.37 (unch), VNDA: 15.38 (-0.34), GNCA: 5.36 (-0.03), DRRX: 1.67 (-0.04)
